The Oxford/AstraZeneca COVID-19 vaccine trial [electronic resource] : adverse patient event reports / an interview with Saad Shakir.
Material type:
SoundSeries: Henry Stewart talksBiomedical & life sciences collection. Interviews on Covid-19: Publisher: London : Henry Stewart Talks, 2020Description: 1 online resource (1 streaming audio file (14 min.))Subject(s): AstraZeneca (Firm) | University of Oxford | Clinical trials | COVID-19 (Disease) | COVID-19 (Disease) -- Vaccination | Vaccines -- Development | ChAdOx1 COVID-19 vaccine | Clinical Trials as Topic | COVID-19 Vaccines -- adverse effects | COVID-19 -- prevention & control | Pharmacovigilance | Research Design | SARS-CoV-2 | Vaccines -- adverse effectsOnline resources: Click here to access online | Series Audio interview.
Title from title frames.
Contents: Mode of action of the Oxford/AstraZeneca RNA vaccine -- Two potential adverse events reported in patients enrolled in the vaccine's phase 3 trial -- Steps undertaken to determine possible causality between the adverse events and the vaccine -- Current status of the trial -- Please note that since the recording of this interview it was determined that "The serious adverse events observed during the trial in these study groups were judged to be unrelated to the study vaccines and occurred at frequencies expected for these conditions in the general population. None of the participants included in this report had any suspected unexpected serious adverse reactions." (Ramasamy et al., The Lancet, November 18, 2020, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext).
Access restricted to subscribers.
Mode of access: World Wide Web.